The interval between the original illness and the relapse is what makes the case extraordinary. Very late relapses of central nervous system germinoma, defined loosely as recurrences appearing many years after complete remission, are rare enough that standardized salvage protocols do not exist. Complicating matters further, this patient already lived with the chronic endocrine consequences of his first tumor and its treatment: central diabetes insipidus, in which the pituitary fails to release antidiuretic hormone and the kidneys excrete dilute urine uncontrollably, and panhypopituitarism, a global deficiency of pituitary hormones requiring lifelong replacement of cortisol, thyroid hormone, and other axes. Any future treatment would have to be layered onto this fragile hormonal scaffolding.

Equally notable was the anatomy of the recurrence. The new tumor sat in the optic nerve within the orbit, a location that fell outside the radiation field used to treat the original suprasellar lesion. That detail matters scientifically because it illustrates how germinoma cells can seed distant neural compartments while evading the very beams intended to eradicate them, and it underscores why long-term surveillance of survivors must extend beyond the treated volume. Imaging also raised suspicion of a hemorrhagic lesion in the right middle cerebellar peduncle, though the team could not obtain a biopsy and cerebral angiography revealed no detectable vascular abnormality, leaving that finding radiographically suspicious but pathologically unconfirmed.

To achieve cure, the oncologists selected a salvage regimen of ifosfamide, cisplatin, and etoposide, the ICE combination that is a workhorse of germ cell tumor therapy. Cisplatin is among the most nephrotoxic drugs in clinical use; it injures the proximal renal tubules, which are responsible for reabsorbing the bulk of filtered sodium, glucose, and other solutes. Ifosfamide adds its own tubular toxicity, and together the two agents can push the kidney into a state where it literally wastes salt into the urine. In a patient whose antidiuretic hormone axis was already absent, the stage was set for a perfect storm of sodium and water derangement.

That storm arrived during the chemotherapy course as symptomatic grade 4 hypotonic hyponatremia, the most severe category of sodium depletion. The patient’s serum sodium fell to 118.4 milliequivalents per liter, with a serum osmolality of 236 milliosmoles per kilogram, values low enough to risk cerebral edema, seizures, and death. Severe hyponatremia of this kind is a medical emergency, but treating it is deceptively complex, because the correction itself must be gradual; raising sodium too quickly can precipitate osmotic demyelination syndrome, a devastating injury to the brainstem. The team responded with hypertonic saline, isotonic fluids, oral salt supplementation, and serial measurement of both serum and urine chemistries.

The most instructive data came from the rechallenge. When the same drugs were given again, the clinical team recorded urine output rising from 1.40 liters per day at the start of the second cycle to 4.25 liters per day by day three and a remarkable 9.75 liters per day by day four, accompanied by high spot urinary sodium concentrations. In other words, the kidneys were dumping enormous volumes of sodium-rich urine precisely when the chemotherapy was on board. This temporal link between drug exposure and massive salt loss is the kind of physiological fingerprint that clinicians use to distinguish drug-induced renal salt wasting from other causes of hyponatremia.

Here, however, the authors are careful about what the evidence can and cannot prove. Because oral intake, intravenous fluid volumes, net fluid balance, objective volume status, and fractional urate excretion were unavailable, they classified the episode as a chemotherapy-associated mixed sodium and water disturbance with a suspected salt-wasting component rather than confirmed renal salt wasting. This distinction is more than academic hair-splitting. True renal salt wasting is treated with aggressive sodium repletion, whereas the syndrome of inappropriate antidiuretic hormone secretion, which can also accompany chemotherapy, calls for fluid restriction. In a patient with central diabetes insipidus on desmopressin, a synthetic antidiuretic hormone, the picture becomes a three-way puzzle: too little antidiuretic hormone by nature, possible inappropriate secretion masked by replacement therapy, and drug-driven tubular salt loss all competing in the same body.

The recurrent toxicity ultimately forced a change in strategy. Cisplatin and ifosfamide were discontinued, and the regimen was switched to carboplatin plus etoposide, a platinum pairing that trades some of cisplatin’s potency for a gentler renal profile. The high-output sodium-wasting pattern attenuated on the new regimen, although grade 3 hyponatremia persisted, indicating that the kidneys remained vulnerable even after the most offending agents were withdrawn. Crucially, the supportive framework of hypertonic saline, isotonic fluids, oral salt, and close laboratory monitoring allowed the team to complete the full curative-intent chemotherapy course and proceed to craniospinal irradiation without abandoning the goal of cure.

The outcome validates that persistence. At the one-year imaging assessment, the patient maintained a complete response, meaning no evidence of active tumor could be detected. For a young man who had already survived one brain germinoma in childhood and then faced a second, out-of-field recurrence a decade later, the achievement of durable remission despite life-threatening metabolic complications is a genuinely encouraging result. It demonstrates that severe electrolyte toxicity, while frightening, can be managed intensively enough to keep a curative treatment plan on track.

The broader lessons of this case-based review extend well beyond a single patient. Survivors of central nervous system germinoma need decades of surveillance, because very late relapses can appear in unexpected, previously unirradiated sites, and chronic pituitary dysfunction reshapes how the body handles every future physiological stress. For oncologists, the case is a warning that platinum and alkylating-agent salvage therapy in patients with pre-existing diabetes insipidus demands obsessive attention to urine output, urinary sodium, and serum osmolality, with early escalation of salt repletion and willingness to modify the regimen. For researchers, it highlights how much remains unknown about the intersection of tubular drug toxicity and hypothalamic-pituitary disease, and how careful documentation of fluid balance in future cases could turn suspicion of renal salt wasting into proof. The report, published open access, adds a valuable data point to the sparse literature on a complication that is easy to miss and dangerous to ignore.

Subject of Research: Chemotherapy-associated hyponatremia during salvage therapy for very late relapse of central nervous system germinoma

Article Title: Chemotherapy-associated hyponatremia during curative-intent salvage therapy for very late relapse of central nervous system germinoma: a case-based review

Article References: Ohkuma, R., Tsurui, T., Ishiguro, T., Ikeda, G., Shimokawa, M., Ariizumi, H., Suzuki, R., Osaka, N., Shiraga, Y., Shimura, K., Hara, H., Nakai, T., Inaba, T., Yamashita, M., Kawamori, S., Sato, A., Shiozawa, E., Tanioka, D., Kubota, Y., … Horiike, A. (2026). Chemotherapy-associated hyponatremia during curative-intent salvage therapy for very late relapse of central nervous system germinoma: a case-based review. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06637-z

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06637-z

Keywords: central nervous system germinoma, hyponatremia, chemotherapy, renal salt wasting, central diabetes insipidus, salvage therapy, optic nerve relapse, cisplatin, ifosfamide, carboplatin, etoposide, late relapse